Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
Anticancer Res. 2024 Nov;44(11):4691-4707. doi: 10.21873/anticanres.17296.
BACKGROUND/AIM: Due to the absence of screening protocols, high-grade serous ovarian cancer (HGSOC) patients are frequently diagnosed at an advanced stage, which significantly reduces the survival rate. Moreover, relapse occurs in approximately 70% of HGSOC patients after primary treatment. Predicting resistance to primary chemotherapy remains a challenge. In the research setting, transcriptomic analyses have emerged as powerful tools for predicting which HGSOC patients are likely to benefit from primary treatment. The aim of this review was to investigate the literature demonstrating the potential of transcriptomic signatures as biomarkers for assessing the risk of resistance to platinum-based chemotherapy.
We conducted a three-step search process on PubMed to systematically review English-language articles published between 2020 and 2024. From the 123 articles retrieved, we included 11 articles that investigated transcriptomic signatures by RNA sequencing in tissues from chemo-sensitive and -resistant HGSOC patients.
We report the clinicopathological data of 727 patients in the experimental cohorts, transcriptomic signatures, and technical aspects. Finally, the review lists 15 publicly available datasets used in the included studies. Furthermore, we investigated the overlap of 167 differentially expressed genes retrieved across the various articles.
We believe this review might offer valuable insights for further studies focusing on predicting platinum resistance and personalized treatments. In addition to discussing the latest findings and potential candidates, we highlight the challenges of validating biomarkers across studies and publicly available datasets. Transcriptomic signatures represent a potential tool for patient stratification, prognosis, and the potential adoption of long-term therapies, such as poly (ADP-ribose) polymerase inhibitors (PARPis).
背景/目的：由于缺乏筛查方案，高级别浆液性卵巢癌（HGSOC）患者经常在晚期被诊断，这大大降低了生存率。此外，大约 70%的 HGSOC 患者在初次治疗后会复发。预测对初次化疗的耐药性仍然是一个挑战。在研究环境中，转录组分析已成为预测哪些 HGSOC 患者可能从初次治疗中获益的有力工具。本综述的目的是调查表明转录组特征作为评估对铂类化疗耐药风险的生物标志物潜力的文献。
我们在 PubMed 上进行了三步搜索过程，以系统地综述 2020 年至 2024 年期间发表的英文文章。从检索到的 123 篇文章中，我们纳入了 11 篇研究组织学敏感和耐药性 HGSOC 患者组织中转录组特征的文章。
我们报告了实验队列中 727 名患者的临床病理数据、转录组特征和技术方面。最后，综述列出了纳入研究中使用的 15 个公开可用的数据集。此外，我们研究了在不同文章中检索到的 167 个差异表达基因的重叠。
我们相信，这篇综述可能为进一步研究预测铂类耐药性和个性化治疗提供有价值的见解。除了讨论最新发现和潜在候选物外，我们还强调了在研究和公开可用的数据集中验证生物标志物的挑战。转录组特征代表了一种用于患者分层、预后和潜在采用长期治疗的潜在工具，例如聚（ADP-核糖）聚合酶抑制剂（PARPi）。
